Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims/hypothesisIndividuals with heterozygous activating mutations of the KCNJ11 gene encoding a subunit of the ATP-sensitive potassium channel (KATP) can usually be treated with oral sulfonylurea (SU) pills in lieu of insulin injections. The aim of this study was to test our hypothesis that younger age at the time of initiation of SU therapy is correlated with lower required doses of SU therapy, shorter transition time and decreased likelihood of requiring additional diabetes medications.MethodsWe performed a retrospective cohort study using data on 58 individuals with neonatal diabetes due to KCNJ11 mutations identified through the University of Chicago Monogenic Diabetes Registry (http://monogenicdiabetes.uchicago.edu/registry). We assessed the influence of age at initiation of SU therapy on treatment outcomes.ResultsHbA1c fell from an average of 8.5% (69 mmol/mol) before transition to 6.2% (44 mmol/mol) after SU therapy (p < 0.001). Age of initiation of SU correlated with the dose (mg kg−1 day−1) of SU required at follow-up (r = 0.80, p < 0.001). Similar associations were observed across mutation subtypes. Ten participants required additional glucose-lowering medications and all had initiated SU at age 13 years or older. No serious adverse events were reported.Conclusions/interpretationEarlier age at initiation of SU treatment is associated with improved response to SU therapy. Declining sensitivity to SU may be due to loss of beta cell mass over time in those treated with insulin. Our data support the need for early genetic diagnosis and appropriate personalised treatment in all cases of neonatal diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · cited 3×
“KCNJ11-related neonatal diabetes can almost always be treated with oral SU therapy in place of insulin [2].”
BackgroundMethodInfluentialLongitudinal study of physiologic insulin resistance and metabolic changes of puberty
Hannon, T. S., Janosky, J., & Arslanian, S. A. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000246097.73031.27 · Cited by 353 · cited 1×
“We hypothesise that this is no coincidence as several studies have demonstrated increased insulin resistance and greater need for insulin secretion at the beginning of adolescence [23, 24].”
BackgroundFormation of a human β-cell population within pancreatic islets is set early in life
Gregg, B. E., Moore, P. C., Demozay, D., Hall, B. A., Li, M., Husain, A., Wright, A. J., Atkinson, M. A., & Rhodes, C. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1206 · Cited by 344 · cited 2×
“It remains to be seen whether patients who initiated SU at an early age and currently require lower doses will eventually have failure of beta cell function and require higher doses or other medications as they age, although early reports suggest that doses remain stable [20, 21].”
BackgroundDiagnosis and treatment of neonatal diabetes: an United States experience†
Støy, J., Greeley, S. A. W., Paz, V. P., Ye, H., Pastore, A. N., Skowron, K. B., Lipton, R. B., Cogen, F. R., Bell, G. I., Philipson, L. H., et al. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00433.x · Cited by 126
Self-citation
Cited by
Hattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319
“The dose required depends mostly on the age at which the patient starts sulfonylurea, as well as the specific mutation.(80,81) Many patients have been able to progressively reduce the dose of sulfonylurea after transition while maintaining excellent glycemic control.”
Self-citationGreeley, S. A. W., Polak, M., Njølstad, P. R., Barbetti, F., Williams, R., Castano, L., Raile, K., Chi, D. V., Habeb, A., Hattersley, A. T., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13426 · Cited by 211
Self-citationHyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells
Brereton, M. F., Rohm, M., Shimomura, K., Holland, C., Tornovsky-Babeay, S., Dadon, D., Iberl, M., Chibalina, M. V., Lee, S., Glaser, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms13496 · Cited by 124
Neonatal Diabetes and the K ATP Channel: From Mutation to Therapy
Ashcroft, F. M., Puljung, M. C., & Vedovato, N. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.02.003 · Cited by 106
Babiker, T., Vedovato, N., Patel, K., Thomas, N., Finn, R., Männikkö, R., Chakera, A. J., Flanagan, S. E., Shepherd, M. H., Ellard, S., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3921-8 · Cited by 90
Metadata
- Authors
- the United States Neonatal Diabetes Working Group, Thurber, B. W., Carmody, D., Tadie, E. C., Pastore, A. N., Dickens, J. T., Wroblewski, K. E., Naylor, R. N., Philipson, L. H., & Greeley, S. A. W.
- Venue
- Diabetologia
- Published
- 2015-04-17
- Volume
- 58
- Issue
- 7
- Pages
- 1430-1435
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2045339813
- Cited by
- 85
- References
- 6
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.